New FDA-Approved Treatment for RKD

The FDA has approved Gazyva® (obinutuzumab) for adults and children ages 2 and older with idiopathic nephrotic syndrome that began in childhood and is frequently relapsing (FRNS) or steroid-dependent (SDNS). More information coming soon. Please visit our Patient Navigation tool for support.

RESOURCES

/

FIND A SPECIALIST

/

CONTACT

Lauren Eva

Chief Operating Officer

Lauren Eva directs the implementation of NephCure’s strategic vision as the Chief Operating Officer. Since joining NephCure in 2014, she’s been privileged to meet many inspiring patient families, witness a multitude of discoveries in research and advances in clinical care, and see NephCure help usher in a new era of potential new treatments for people impacted by rare, protein-spilling kidney diseases.

Lauren has a B.A. in International Relations from Michigan State University. She lived in Detroit, Colombia, Chicago, and Philadelphia, serving in various other educational and community-based nonprofit roles, before returning to her hometown in northern Michigan to raise her young daughters. She serves on the board of education of her local public school and co-founded a nature-based Montessori preschool in 2020.

Detroit, MI

Related News

NEWS

NephCure Celebrates C3G Awareness Day on September 25, 2026

NEWS

NephCure Specialist of the Month: Dr. Rupali Avasare

NEWS

Making History on Capitol Hill: Record Advocates Unite for NephCure’s Largest Hill Day Ever

NEWS

NephCure Specialist of the Month: Dr. Fahad Aziz

Sign up to get NephCure’s latest updates.

SIGN UP
This field is for validation purposes and should be left unchanged.